Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

A recruitment drive is underway at Diamyd Medical’s new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden.
“This move gives us greater control and more knowledge about our study drug. Personally it feels fantastic to be involved in building a vaccine facility from the ground up”, says Maja Johansson, Site Manager in Umeå.

Read more

New US agreement proclaimed “significant milestone” for Inficure Bio

Swedish Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases.
“We will now begin testing the effects of their drug substances in our unique model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia Mayans.

Read more

HiloProbe Awarded SEK 2 Million by Swedish Innovation Agency

HiloProbe has been granted SEK 2 million from Swedish Innovation Agency Vinnova to validate a product that detects and helps treat people with colorectal cancer.
“This is an important grant for us and means we can validate our product and make it available to the healthcare industry sooner,” says Lina Olsson, CEO of HiloProbe.

Read more

Swedish biotech company Lipigon hopes to help millions of Covid-19 patients

Umeå-based Lipigon Pharmaceuticals has signed agreements with universities in Shanghai and Shenzhen to develop a new drug that can potentially reduce the number of deaths linked to Covid-19.
“Right now there are very few treatments available for Acute Respiratory Distress Syndrome (ARDS), which can be fatal to some Covid-19 patients. The standard treatment is oxygen and the use of respirators. We hope to change that,” says Lipogon’s CEO, Stefan K Nilsson.

Read more

New and Different Facebook Group Helping Life Science Companies

A new and different Facebook group is enabling companies in the Umeå region to buy and sell second-hand laboratory equipment, as well as gain access to cheaper lab services.
“Umeå University, the County Council and a number of life science companies in Umeå are often in need of a laboratory, but new equipment is expensive and requires a great deal of knowledge to operate. This new Facebook group allows Umeå companies to sustainably support each other,” says Jennie Ekbeck, CEO of Umeå Biotech Incubator.

Read more

Lipigon attracts SEK 16.6 Million in new investment round to fight cardiovascular disease

Umeå-based Lipigon Pharmaceuticals has attracted SEK 16.6 Million in a new share issue that will help it get nearer to its goal of reducing the number of global deaths caused by cardiovascular disease.
“We are extremely proud our new shares issue was oversubscribed, particularly during the ongoing Coronavirus pandemic when many investors are feeling more cautious. It is an indication of the level of belief in us,” says Stefan K Nilsson, CEO of Lipigon.

Read more

QureTech Bio has secured a US patent for tuberculosis treatment

Umeå-based QureTech Bio has received preliminary approval for a patent application in the US for a drug candidate that helps treat tuberculosis.
“The US is a key market for us so this news really helps strengthen our position. We are at a very exciting stage right now,” says Fredrik Almqvist, CEO of QureTech Bio.

Read more

Key appointments being made at new diabetes vaccine facility in Umeå

Construction of Diamyd Medical’s new vaccine manufacturing unit in Umeå is now underway, with a number of key roles being actively recruited to help staff the new facility. Newly-appointed site manager Maja Johansson is responsible for establishing the process for the production of GAD, the active substance in the study drug Diamyd.

Read more

HiloProbe attracts millions in new investment round

Umeå biotech company HiloProbe has attracted millions in new investment capital after successfully developing a diagnostic and prognostic product for colon and rectal cancer.
“Capital is crucial for getting our product to patients and helping them,” says Lina Olsson, HiloProbe’s CEO.

Read more

Agrisera acquired by Uppsala life science company Olink

After many years of private ownership, Vännäs-based Agrisera has been acquired by Swedish biotech company Olink Proteomics AB.
“The Agrisera brand was very strong in itself, but this step offers us great opportunities that can benefit both our customers and partners,” says Erika Gelfgren, CEO of Agrisera.

Read more

Lipigon signs major new deal with Shanghai-listed HitGen

Umeå-based Lipigon Pharmaceuticals AB has signed a major new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases.
“We want to create effective treatments and contribute to a better quality of life for patients,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Recruitment drive at UmanDiagnostics continues as orders anticipated to rise

Last summer Umeå-based UmanDiagnostics was acquired by major US life science company Quanterix for $22.5 million. Now it is recruiting additional staff at its offices in Umeå to meet an expected rise in new orders.
“We’re continuing to invest and are confident we’ll come out of the Coronavirus crisis even stronger, despite the uncertainty being faced by many industries,” says Niklas Norgren, CEO of UmanDiagnostics.

Read more

Pro Test receives 17 million – for blood doping test

Pro Test Diagnostics has developed a unique antidoping kit for blood doping, which will soon be out on the market. The company now takes in SEK 17 million in capital from Nascent Invest AB and the co-owner Fort Knox Förvaring AB.
“Sports federations all over the world, testing agencies and the International Olympic Committee all signal that there is a great need in the market. Thanks to new capital, we are taking a step in the fight against blood doping”, says Anders Mannelqvist, CEO of Pro Test Diagnostics.

Read more

QureTech Bio granted millions to fight antibiotic resistance

Umeå life science company QureTech Bio has received a SEK 3 million grant from the Swelife innovation programme (funded by the Swedish Government via Vinnova) to make antibiotic-resistant bacteria sensitive to different antibiotics again.
“We are delighted to receive this grant, as it will enable us to create a product that can help patients and save lives,” says Fredrik Almqvist, CEO of QureTech Bio.

Read more

Memotus App at forefront of digital healthcare

Umea-based health technology company Instrube Health AB has developed a new communication app for the healthcare industry. Called Memotus, the new messaging app and platform is designed for both healthcare providers and patients, allowing them to manage consultations and follow-up visits digitally.
“We are now ready to supplement physical care by offering healthcare providers a digital communication tool”, says Mikael Östberg, CEO of Instrube Health.

Read more

Lipigon signs new deal in billion dollar market

Umeå-based Lipigon Pharmaceuticals has signed a new deal and taken over the patent portfolio for a number of drug candidates that could help treat cardiovascular diseases.
“The market in treatments for various blood fat disorders amounts to several billion dollars. This is a very important opportunity for us,” says Stefan K Nilsson, CEO of Lipigon.

Read more

More new recruitments at Umeå Biotech Incubator

Umeå Biotech Incubator (UBI) is strengthening its team once again with the appointments of a new Business Coach and Community Manager.
“The pressure is on! Right now we have a lot of ideas developing at our incubator and several of our companies are looking to take the next step. That’s why it is so important we have sufficient resources to handle this growth”, says Jennie Ekbeck, CEO of UBI.

Read more

Biotech Expert Joins Lipum Board

Dr Kristian Sandberg, Director of the Drug Discovery and Development platform at SciLifeLab, has joined the board of Umeå-based biotech company Lipum.
“Kristian has extensive experience in drug development. We are absolutely delighted to announce his appointment”, says Ulf Björklund, Chairman of the Board at Lipum.

Read more